866-997-4948(US-Canada Toll Free)

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Oct 2016

Category :

Pharmaceutical

No. of Pages : 110 Pages

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016, provides in depth analysis on Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted pipeline therapeutics.

The report provides comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
- The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Overview 10
Therapeutics Development 11
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Stage of Development 11
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Therapy Area 12
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Indication 13
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Companies 17
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Universities/Institutes 21
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment 23
Assessment by Monotherapy/Combination Products 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development 29
Akari Therapeutics, Plc 29
Alexion Pharmaceuticals Inc 30
Alnylam Pharmaceuticals, Inc. 31
Amgen Inc. 32
Epirus Biopharmaceuticals, Inc. 33
F. Hoffmann-La Roche Ltd. 34
InflaRx GmbH 35
Novartis AG 36
Noxxon Pharma AG 37
Ophthotech Corp. 38
Ra Pharmaceuticals, Inc. 39
Swedish Orphan Biovitrum AB 40
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles 41
AcPepA - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ALN-CC5 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ALXN-1007 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
ALXN-1210 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
ALXN-5500 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
avacincaptad pegol sodium - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Bikaciomab - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
BikajuMab - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Coversin - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Coversin LA - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
eculizumab - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
eculizumab biosimilar - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
eculizumab biosimilar - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
IFX-1 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
IFX-2 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Mubodina - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
NM-9405 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
NOXD-19 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
NOXD-20 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
NOXD-21 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Protein to Inhibit Complement C5 for Immunology - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
RA-101295 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
RA-101348 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
RA-101495 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
RO-7112689 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
SOBI-005 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Autoimmune Disorders - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
tesidolumab - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Projects 91
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products 94
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Featured News & Press Releases 95
Sep 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria 95
Aug 29, 2016: European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease 95
Jul 13, 2016: Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria 96
Jul 12, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria 96
Jul 07, 2016: New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress 97
Jul 06, 2016: Federal Court Dismisses Challenge to Constitutionality of Federal Government's Drug Price Watchdog 99
Jul 06, 2016: Akari Therapeutics Announces Positive Interim Update from Phase Ib Trial Demonstrating Sustained Complement Inhibition Using Once-Daily Subcutaneous Maintenance Dosing with Coversin 99
Jun 11, 2016: Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from Ongoing Phase 1/2 Study 100
Jun 10, 2016: Alexion Pharmaceuticals Presented data on ALXN1007 at 21st Congress of the European Hematology Association 102
Jun 10, 2016: Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH 103
Jun 10, 2016: Ra Pharmaceuticals Presents Clinical Data on Complement C5 Inhibitor RA101495 at the 21st Congress of the European Hematology Association 104
Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery 105
Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG) 106
Jun 03, 2016: Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data 108
Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) 108
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 109
Disclaimer 110

List of Tables
Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Indication, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Development by Companies, H2 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Products under Investigation by Universities/Institutes, H2 2016 22
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Pipeline by Akari Therapeutics, Plc, H2 2016 29
Pipeline by Alexion Pharmaceuticals Inc, H2 2016 30
Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 31
Pipeline by Amgen Inc., H2 2016 32
Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016 33
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 34
Pipeline by InflaRx GmbH, H2 2016 35
Pipeline by Novartis AG, H2 2016 36
Pipeline by Noxxon Pharma AG, H2 2016 37
Pipeline by Ophthotech Corp., H2 2016 38
Pipeline by Ra Pharmaceuticals, Inc., H2 2016 39
Pipeline by Swedish Orphan Biovitrum AB, H2 2016 40
Dormant Projects, H2 2016 91
Dormant Projects (Contd..1), H2 2016 92
Dormant Projects (Contd..2), H2 2016 93
Discontinued Products, H2 2016 94

List of Figures
Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Top 10 Indication, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Actions, H2 2016 24
Number of Products by Routes of Administration, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 25
Number of Products by Molecule Types, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *